Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$76.43 USD

76.43
4,057,648

-3.15 (-3.96%)

Updated May 1, 2024 04:00 PM ET

Pre-Market: $77.41 +0.98 (1.28%) 9:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VKTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Viking Therapeutics, Inc. [VKTX]

Reports for Purchase

Showing records 41 - 60 ( 210 total )

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

02/09/2023

Company Report

Pages: 8

2022 Results; Three Data Shots on Goal With VOYAGE Leading Charge; Reiterate 2023 Top Pick

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

01/09/2023

Company Report

Pages: 7

VK2809 Prepping For NASH Top-Line Data Readout in 1H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

12/19/2022

Company Report

Pages: 7

Great Readthrough For VK2809; Phase 2b VOYAGE Readout Anticipated 1H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

10/27/2022

Company Report

Pages: 6

3Q22 Results; Time''s a Comin''; Critical Data Readouts Expected by 1H23; Reit. Buy and $21 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

10/27/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

10/27/2022

Company Report

Pages: 8

3Q22 Recap - Data (3X) Coming in 2023

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

08/02/2022

Company Report

Pages: 8

2Q22 Recap - Enrollment Completion Expected by Year-End

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

08/02/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

07/28/2022

Company Report

Pages: 6

2Q22 Results; Three-Pronged Approach Advances; Multiple Data Readouts in Next 12 Months

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

07/19/2022

Daily Note

Pages: 6

VK0124 Clinical Program Gets FDA Nod to Restart; Pushing Toward Key VK2809 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

04/28/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

04/28/2022

Company Report

Pages: 8

1Q22 Results; Clinical Programs Continue to Advance; VK2809 and VK2735 Updates Expected by Year End

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

04/27/2022

Company Report

Pages: 9

1Q22 Recap - Enrollment Completion Targeted for 2H22

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

02/10/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

02/10/2022

Company Report

Pages: 7

2021 Results; Focus on VOYAGE End Game and Pipeline Visibility This Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

02/10/2022

Company Report

Pages: 8

4Q21 Recap - Data Still a 2022 Event

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

01/31/2022

Daily Note

Pages: 5

Confidence Around VK2809''s MoA Swells Ahead of VOYAGE; Top Line Data in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

01/27/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Viking Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

01/27/2022

Company Report

Pages: 8

Approaching Carcass Value

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party